Dr. Stephen A. Bloom, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Connecticut School of Medicine (1981)
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,135
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1981Medical school: University of Connecticut School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
KS license 0421697 · LA license 329171 · MO license R6G52
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Shawnee Mission Shawnee Mission, KS
- Centerpoint Medical Center Independence, MO
- Research Medical Center Kansas City, MO
- Menorah Medical Center Overland PArk, KS
- Overland PArk Reg Med Ctr Overland PArk, KS
Medical groups
- Midwest Heart and Vascular Specialists LLC (80 clinicians)
- Encompass Medical Group PA (43 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,135
- Services billed
- 2,771
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 543 | 327 |
| Established patient office or other outpatient visit, 30-39 minutes | 435 | 267 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 399 | 384 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 354 | 173 |
| Heart muscle strain imaging | 282 | 272 |
| Ct scan of heart structure with contrast | 201 | 194 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 185 | 182 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 98 | 98 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 79 | 77 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 77 | 76 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 16 payments worth $528 in total to this clinician.
| Cleerly, Inc. | $173 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $109 |
| AstraZeneca Pharmaceuticals LP | $70.34 |
| Novo Nordisk Inc | $36.15 |
| Amgen Inc. | $30.65 |
| Recor Medical Inc | $29.38 |
| Pfizer Inc. | $17.84 |
| Alnylam Pharmaceuticals Inc. | $16.57 |
| Food and Beverage | $528 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $203,598 in research payments for these studies, mostly to the institutions running them.
- Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - Confirm2
Cleerly, Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENT…
Novartis Pharmaceuticals Corporation - A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiogra…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.